



Fiscal year ended August 2026

Financial Results Presentation

Chordia Therapeutics Inc.
(TSE securities code: 190A)


October 15, 2026

Table of Contents

1.	Corporate Overview	P.	3
2.	FY2026 Highlights and Review	P.	6
3.	FY2026 Financial Results and Financial Position	P.	9
4.	Pipeline Progress	P.	14
5.	Key Priorities for FY2027	P.	23

Corporate Overview and Business History

Company Profile	Name	Chordia Therapeutics Inc	Establishment	October,12,2017	Head Office	Fujisawa, Kanagawa, Japan	Paid-in Capital	¥1,345 million
	Securities code	190A	Representative	Hiroshi Miyake	Employees	22 personnel (incl, 12 PhD)	Total Funding Raised	Approx. ¥10.8 billion



Management Team Driving Growth with Diverse Expertise

- CEO and expert external directors driving growth through agile decision-making

Representative



CEO
Hiroshi Miyake

- Co-founded Chordia Therapeutics in October 2017; appointed as CEO
- Over 20 years in drug discovery at Takeda; Japan Site Head of Oncology, contributing to six clinical
- B.S. in Pharmaceutical Sciences, Osaka University; Ph.D. in Pharmaceutical Sciences, The University of Tokyo

External Director



Strategy

Manabu Nakamura

(Representative Director,
Shinsei Capital Partners Co., Ltd)

External Director



Strategy

Yutaka Tsuchiya

(Former Representative Executive Officer of
Eisai Co., Ltd.; External Director at Maruho Co.,
Ltd.)

External Director



Strategy

Seiji Hirasaki

(Former Director, AnGes Inc.; Former
President & CEO, Oriciro Genomics Inc.)

Audit and Supervisor Committee member (External Director)



Accounting

Kosuke Ishii

(CPA/External Director,
RaQualia Pharma Inc.)



R&D

Yukari Nishikata

(Former Head of Oncology Unit,
Japan and Asia, Takeda
Pharmaceutical Company Limited)



Law

Ayuko Hashimoto

(Attorney, Kotto-dori Law Office)

Table of Contents

1.	Corporate Overview	P.	3
2.	FY2026 Highlights and Review	P.	6
3.	FY2026 Financial Results and Financial Position	P.	9
4.	Pipeline Progress	P.	14
5.	Key Priorities for FY2027	P.	23

Advancing R&D and Strengthening Our Business Foundation

R&D



Corporate Activities

Strengthening Our Business Foundation

- Major AMED Grant Awarded (up to ¥1.5 billion; 50% of eligible international clinical trial costs covered)
- Collaborative Research Initiated in the Ophthalmology Field

IR Activities (Expanded Investor Engagement Through Proactive IR Activities in Japan and Overseas)

- Expanded Investor Outreach in Japan and Overseas
- Participation in International Investor Conferences (BIO International Convention 2026, BIO Asia–Taiwan 2026)
- Participation in Retail Investor Seminars and Investment Events

FY2026 Review



Achieved

Clinical trial progress for approval of rogocekib (CTX-712)

- Initiation of expansion cohort in U.S. Phase 1/2 trial to accelerate enrollment
- Interim Phase 1 results presented at a major international conference, supporting trial advancement

Achievement Status

- Initiation of the Expansion Cohort
- Presented Interim Results from the Phase 1 Portion at EHA



Not Achieved

Proactively engage in new business alliances

CTX-177 is a priority for re-licensing and actively advanced. Leveraging CTX-712, we continue partnership discussions for CTX-439, GCN2, and other programs globally. Business discussions are ongoing, with timely disclosure upon completion.

Achievement Status

Not Achieved

Ongoing

- Re-outlicensing of CTX-177 (Termination Agreed)
- Continued Out-licensing Activities



Achieved

Properly execute disclosure to shareholders

Research progress will be disclosed at domestic and international conferences (≥1 presentation annually). Investor communication is a key priority, including seminars and CEO messaging via media channels.

Achievement Status

- Participation in Retail Investor Seminars and IR Events
- Publication of Equity Research Reports on the Corporate Website

Summary: R&D and disclosures progressed largely as planned, while no partnership was achieved. We will focus on enhancing corporate value through clinical development, business development, and strengthening our financial foundation, including through AMED GRiT grants.

Table of Contents

1.	Corporate Overview	P.	3
2.	FY2026 Highlights and Review	P.	6
3.	FY2026 Financial Results and Financial Position	P.	9
4.	Pipeline Progress	P.	14
5.	Key Priorities for FY2027	P.	23

FY2026 Financial Results (Statement of Income)

- R&D expenses decreased year on year: U.S. CRO costs rose with the initiation of the expansion cohort, but manufacturing-related costs were limited as the drug substance and drug product required for the trial had already been secured.

Unit : Million Yen

	FY2025 (Actual)	FY2026 (Actual)	Change
Revenue	-	-	-
Direct Expenses	-	-	-
R&D Expenses	1,425	1,155	△270
rogocekib (CTX-712)	1,067	795	△272
CTX-177	0	10	+ 10
CTX-439	27	19	△8
Other (incl. personnel expenses)	331	330	△1
Other G&A Expenses	364	318	△46
Operating Loss	△1,789	△1,473	+ 316
Non-op. / Extraordinary Income	24	56	+ 32
Non-op. / Extraordinary Losses	17	35	+ 18
Loss Before Income Taxes	△1,783	△1,452	+ 331
Income Taxes	2	2	—
Net Loss	△1,785	△1,455	+ 330

Key Points for FY2026

● rogocekib: CTX-712 (CLK):

- Based on data from 42 patients in the Phase 1/2 trial, a dosing regimen meeting the expansion criteria was identified; IE cohort initiated in March 2026.
- U.S. CRO costs increased (+¥248 million) due to IE cohort initiation and milestone-related costs.
- API and formulation-related costs decreased (-¥521 million).

● Other G&A Expenses:

- Lower size-based enterprise tax following capital reduction
- Lower patent-related costs
- Effect of fixed-cost reduction measures

FY2026 Financial Position (Balance Sheet)

- Financing through the exercise of the 9th Series Stock Acquisition Rights brought cash and deposits to ¥2,052 million as of August 31, 2026, securing the funds required for business activities over the next 12 months and maintaining the financial foundation.

	Unit : Million Yen		
	Aug 31, 2025 (Balance)	Aug 31, 2026 (Balance)	Change
Current Assets	2,669	2,102	△567
Cash and deposits	2,548	2,052	△496
Others	120	50	△70
Non-current Assets	12	12	-
Total Assets	2,681	2,114	△567
Current Liabilities	244	188	△56
Non-current Liabilities	-	-	-
Total Liabilities	244	188	△56
Total Net Assets	2,437	1,925	△512
Total Liabilities and Net Assets	2,681	2,114	△567

Key points for FY2026

- **Current Assets / Net Assets:**
 - Cash and deposits: ¥1,418 million used in operating activities, partially offset by ¥927 million in proceeds from the exercise of stock acquisition rights.
 - Net assets: Increase from share issuance, offset by the net loss for the fiscal year.

Financing through the 12th Series Stock Acquisition Rights

●Following the securing of operating funds for the next year, Chordia completed additional financing to maintain flexibility for the completion of the rogocekib expansion cohort, Phase 2 preparation and future development activities, while further concentrating resources on rogocekib.

¥1,506million

Estimated Net Proceeds
(Based on Initial Exercise Price)

23.84%

Maximum Dilution Ratio
(24.99% on a Voting Rights Basis)

Approx. 2years

Exercise Period
(Sep 11, 2026 - Sep 8, 2028)

Offering Details	
Allottee	Nomura Securities Co., Ltd.
Board Resolution Date	August 24, 2026
Allotment and Payment Date	September 9, 2026 (Payment Completed)
Total Number Issued	184,220 Units
Underlying Shares	18,422,000 Shares
Exercise Price	Initial Price: ¥82 / Floor Price: ¥41 (Subject to Exercise Price Adjustment Mechanism))
Key Terms	Includes Exercise Suspension Provision

Use of Proceeds

- Completion of the rogocekib expansion cohort and execution of the drug-drug interaction (DDI)
- Advancement of development activities toward initiation of the Phase 2 clinical trial in the second half of FY2027
- Promotion of development activities, including global collaborative discussions, leveraging non-dilutive funding sources such as AMED

Treatment of Existing Stock Acquisition Rights

- 9th Series: Remaining rights acquired and cancelled on September 9, 2026.
- 10th and 11th Series: Maintained as financing alternatives. To enable flexible financing, Chordia instructed suspension of the exercise of the 12th Series rights.

Source: Timely disclosures issued by the Company on August 24, 2026 and September 9, 2026. Actual proceeds may vary depending on the exercise status of the stock acquisition rights and fluctuations in the share price.

AMED GRIT Program Selected

● rogocekib global clinical development program selected for AMED’s GRIT program, with expected support of up to ¥1.5 billion.

Project Details		About GRiT	
■ Program	FY2026 AMED “Innovative Medical Technology Research and Development Promotion Program (Industry-Academia Collaboration) - Global Research and Development Support Project for Intractable and Rare Diseases” (GRIT)	An AMED initiative that supports global clinical trials to accelerate commercialization of therapeutics for intractable and rare diseases.	
■ Project	Phase 1/2 clinical trial of CTX-712 (rogocekib) for relapsed/refractory AML and high-risk MDS	Global Research and Development Support Project for the Treatment of Intractable / Rare Diseases	
■ Expected Funding	Eligible to receive competitive funding of up to ¥1.5 billion (covering up to 50% of eligible costs for the global trial)	Scope	Global clinical trials for therapeutics targeting intractable and rare diseases
■ Development Plan	Advance development as a global clinical trial including Japan	Subsidy Rate	Up to 50% of eligible project costs
■ Orphan Drug Designation	Granted Orphan Drug Designation by the U.S. FDA (AML) and designated as an Orphan Drug in Japan	Funding Cap	Up to ¥1.5 billion ※ Actual funding amount to be determined based on future research plans.
		Project Period	Generally up to three years

Advancing rogocekib’s global development for rare hematologic malignancies with public funding support.

Source: AMED GRIT program information and the Company's timely disclosure dated September 30, 2026.

Table of Contents

1.	Corporate Overview	P.	3
2.	FY2026 Highlights and Review	P.	6
3.	FY2026 Financial Results and Financial Position	P.	9
4.	Pipeline Progress	P.	14
5.	Key Priorities for FY2027	P.	23

Of the five pipelines, two are in the clinical stage

— Strategic focus on rogocekib, which has high market potential, to accelerate value creation


- Focus resources on rogocekib and advance development in Japan and the U.S. through in-house development or partnerships.
- Assess monetization opportunities for other pipelines (CTX-177/CTX-439/GCN2) via out-licensing

	Target	Code	Common name	Target cancer type	Development stage	Current assumed options
①	CLK	CTX-712	rogocekib	Acute myeloid leukemia, myelodysplastic syndrome, ovarian cancer, and more	Ph1 in JP completed, Ph1/2 in US are ongoing	JP&US:In house development/ Partnership
②	MALT1	CTX-177	ocipumaltib	Lymphoma	P1 clinical trials	Partnership
③	CDK12	CTX-439		Solid tumors	Pre-clinical trials have been complete	Partnership
④	GCN2	None		Solid tumors, hematological tumors	Pre-clinical trials	Partnership
⑤	Undisclosed	None		Solid tumors, hematological tumors	Pre-clinical trials	Partnership

Rogocekib CTX-712 (CLK) : Advancing the Expansion Cohort

Objectives of
expansion cohort

Determine recommended dose and target indications based on safety and efficacy evaluation



rogocekib : Overview of Interim Results Presented at EHA 2026

- Presented data from the dose-escalation cohort in patients with relapsed/refractory myeloid malignancies who have limited treatment options.

Presentation Overview

Item	Content
Conference	European Hematology Association (EHA) 2026 Congress, Stockholm, Sweden (June 11-14, 2026)
Presentation No. / Format	EHA-3974 / Poster Presentation (June 13, 2026)
Study	Phase 1/2 Clinical Trial in the U.S. (CTX-712-CL-02), Dose-Escalation Cohort
Patient Population	MDSRelapsed/Refractory AML, High-Risk MDS, and MDS/MPN (including CMML)
Number of Patients	42Patients
Dosing Schedule	Oral administration once weekly (QW) or twice weekly (BIW)

Patient Characteristics (n=42)— Predominantly elderly patients with extensive prior treatment history and poor prognostic risk factors.

33.3%
75+ years

57.1%
≥3 Prior Regimens

73.9%
Adverse-risk AML
(ELN 2017 Adverse)

Disease Distribution



Major Genetic Mutations :
SRSF2 32.4%、SF3B1 17.6%、U2AF1 8.8%、ZRSR2 5.9%
(Among patients with MDS, 73.7% were classified as IPSS-R High/Very High risk.)


Glossary
Relapsed or Refractory: Disease that is resistant to treatment or recurs after an initial response.
Myeloid Malignancies: Blood cancers arising from abnormal myeloid cells, including AML and MDS.

Source: Supplementary presentation materials for the Company's EHA 2026 interim results presentation (EHA-3974) dated June 15, 2026. Data cutoff: April 30, 2026.


rogocekib : Safety (EHA 2026)

- A manageable safety profile was observed, with gastrointestinal adverse events being the most common and hematologic toxicities remaining limited.

Frequency of Major Adverse Events (n=42)



Maximum Tolerated Dose (MTD) and Dose-Limiting Toxicities (DLT)



DLT Cohort	No. of Patients	Adverse Events
80mg QW	1	Hypotension
140mg QW	2	Dyspnea, Pericardial Effusion, Chest Pain, Hypotension
80mg BIW	1	Esophagitis with Bleeding
100mg BIW	1	Increased ALT, Increased AST

Source: Supplementary presentation materials for the Company's EHA 2026 interim results presentation (EHA-3974), dated June 15, 2026. Data cutoff: April 30, 2026.

rogocekib : Efficacy (EHA 2026)

●Single-agent antitumor activity was observed in patients with relapsed or refractory disease.

11.8%

Overall Response Rate (ORR) :
4 of 34 evaluable patients
(CRi (n=3), mCR (n=1))

29Days

Median Time to Response
Responses observed in approx. 1 month

157Days

Median Duration of Response
Responses maintained for approx. 5 months

Response Rate by Subgroup

Patient Population / Dose	Response	Response Rate
AML / 100mg QW	CRi	50% (2/4 patients)
AML / 80mg BIW	CRi	20% (1/5 patients)
MDS / 80mg QW	mCR	25% (1/4 patients)
Ref.: Japan Phase 1 (CL-01) AML 12, MDS 2; 70/105 mg BIW	CR 4 CRi 1 MLFS 1	ORR 42.9% (6/14 patients)

Key Findings

Single-Agent Activity in Both Japan and U.S. Studies

- Responses observed in both the Japan (ORR 42.9%) and U.S. (ORR 11.8%) studies; not directly comparable due to differences in patient background and dosing (incl. low doses in the U.S.). Reproducibility to be verified in the expansion cohort.

Responses in Venetoclax-Resistant Cases

- All 3 AML patients with CRi were venetoclax-resistant; 2 had ≥4 prior regimens.

Reduction in Blast Counts

- Overall: ≥50% blast reduction in 10 of 27 patients
- Splicing factor mutation-positive: 5 of 14 patients

*Subgroups are small and require confirmation in the expansion cohort; cross-trial comparisons are not appropriate.
*Japan Phase 1 data are for reference only (different patient background and dosing) and are not directly comparable with the EHA 2026 data.


Glossary
ORR (Overall Response Rate): Percentage of patients achieving CR, CRi, MLFS (AML), or mCR (MDS).
CR: Complete Remission; CRi: Complete Remission with Incomplete Hematologic Recovery; MLFS: Morphologic Leukemia-Free State; mCR: Marrow Complete Remission

Source: Supplementary presentation materials for the Company's EHA 2026 interim results presentation (EHA-3974), dated June 15, 2026. Data cutoff: April 30, 2026.

Development Milestones for rogocekib

— Steady Progress with 129 Patient Enrollments Across Japan and the U.S.


- Patient enrollment in the clinical trials continues to progress steadily, with a total of 129 patients enrolled in Japan and the U.S. as of August 31, 2026. In addition to having received Orphan Drug Designation from the U.S. FDA, rogocekib was also granted Orphan Drug Designation in Japan in August 2026 for the treatment of relapsed or refractory AML.
- Rogocekib was selected for AMED's GRiT program in September 2026. The Company is considering earlier enrollment at Japanese sites (previously planned from Phase 2) and will determine the development strategy and target filing timing based on AE cohort results. Details will be disclosed once finalized.



Monetization Strategy and Focus

—Strategy (shortened timelines) × Focus (small molecules, first-in-class, precision)

- Accelerated value creation by shifting focus from discovery to clinical research, significantly shortening development timelines
- Risk reduction and higher returns through small molecules (low manufacturing risk), first-in-class (global novelty), and precision medicine (higher success probability)
- Development capabilities comparable to major pharmaceutical companies (50% PhD holders) driving execution



Diversified Capital Strategy under Uncertainty

- As clinical data accumulates in Japan and the U.S. (reducing risk and uncertainty while increasing value), a broader range of capital strategy options becomes available.




Table of Contents

1.	Corporate Overview	P.	3
2.	FY2026 Highlights and Review	P.	6
3.	FY2026 Financial Results and Financial Position	P.	9
4.	Pipeline Progress	P.	14
5.	Key Priorities for FY2027	P.	23

Key Priorities for FY2027

● Advance the development of rogocekib toward initiation of a Phase 2 clinical trial, while maintaining optionality including strategic partnerships to maximize value.

1

Development

Development of rogocekib toward Phase 2 Initiation

Transition from IE to AE based on IE results, and evaluate and prepare for global clinical development including Japan, leveraging AMED GRiT.

Key Initiatives

- Initiation of the AE cohort
- Determination of RP2D (recommended dose) and target indications
- Preparation for a global clinical trial including Japan, leveraging AMED GRiT
- Decision on Phase 2 development strategy based on AE cohort evaluation (mid-2027)

2

Business Development

Business Development for Value Maximization

Pursue partnership opportunities in Japan and overseas to maximize pipeline value, without limiting timing or structure.

Key Initiatives

- rogocekib: partnership discussions leveraging clinical data
- ocipumaltib: business development, including re-licensing
- CTX-439 and GCN2: evaluation of early partnering

3

Financial Foundation

Strengthening the Financial Foundation

Enhance corporate value through timely communication of development progress and steadily secure development funding.

Key Initiatives

- Advance financing through the 12th Series Stock Acquisition Rights via timely and appropriate disclosure of development progress
- Reduce global clinical trial costs by leveraging AMED GRiT
- Improve fixed-cost efficiency and concentrate resources on rogocekib

*Timing reflects current expectations and may change depending on development progress, discussions with regulatory authorities, and the external environment.

Management policies and 2030 vision

**Building a world where
tomorrow is another day!**

**Delivering the world's first made-in-Japan new
anticancer drugs to patients as soon as possible**

———— Mission ————

We are passionate to deliver first-in-class cancer drugs to patients.

———— 2030 Vision ————

To be an R&D-oriented pharmaceutical company based in Japan.

Four compound patents supported by multiple use and process patents

- In addition to holding compound patents licensed from Takeda Pharmaceutical with sufficient remaining term, we are actively securing intellectual property rights for clinical-stage programs through the acquisition of method-of-use and process patents. The number of registered countries continues to increase steadily

	Application #	Application date	Publication date	Patent #	Registered countries	Substance patent Assignee(s)
rogocekib CTX-712 (CLK inhibitor)	PCT/JP2017/016717	Apr. 28, 2016	Nov. 2, 2017	WO2017/188374	51	Takeda
	PCT/JP2023/013361	Mar. 31, 2022	Oct. 5, 2023	WO2023/190967	—	Chordia & National Cancer Center Japan
	PCT / JP2025/000724	Jan. 12, 2024	Jul. 17, 2025	WO2025/150571	—	Chordia
ocipumaltib CTX-177 (MALT1 inhibitor)	PCT/JP2019/046261	Nov. 28, 2018	Jun. 4, 2020	WO2020/111087	18	Takeda
	PCT/JP2021/019911	May 27, 2020	Dec. 2, 2021	WO2021/241611	2	Takeda
	PCT/JP2023/003154	Feb. 2, 2022	Aug. 10, 2023	WO2023/149450	—	Chordia
CTX-439 (CDK12 inhibitor)	PCT/JP2019/013531	Mar. 29, 2018	Oct. 3, 2019	WO2019/189555	51	Takeda
— (GCN2 inhibitor)	PCT/JP2017/028928	Aug. 10, 2016	Feb. 15, 2018	WO2018/030466	50	Takeda

Disclaimer

- This presentation has been prepared solely for the purpose of presenting relevant information regarding Chordia Therapeutics Inc. (the “Company” or “Chordia”). This presentation does not constitute or form part of and should not be construed as, an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company in Japan, the United States or any other jurisdictions.
- The information contained herein is based on current economic, regulatory, market trends and other conditions. The Company makes no representation or guarantee with respect to the credibility, accuracy or completeness of the information herein. The information contained herein may change without prior notice. You may not publish or use this presentation and the contents thereof for any other purpose without prior written consent of the Company. Furthermore, the information on future business results are forward-looking statements. Forward-looking statements include but are not limited to expressions such as “believe,” “expect,” “plan,” “strategic,” “anticipate,” “predict” and “possibility,” as well as other similar expressions to explain future business activities, achievements, events and future conditions. Forward-looking statements are predictions about the future that reflect management’s judgment based on currently available information. As such, these forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from those expressed in or suggested by the forward-looking statements. Therefore, you may not rely entirely on forward-looking statements. The Company does not assume any obligation to change or correct any forward-looking statements in light of new information, future events or other findings. This presentation contains statements that constitute forward-looking statements, including estimations, forecasts, targets and plans. Such forward-looking statements do not represent any guarantee by management of future performance. Any forward-looking statements in this presentation are based on the current assumptions and beliefs of the Company in light of the information currently available to it, and involve known and unknown risks, uncertainties and other factors. Such risks, uncertainties and other factors may cause the Company’s actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by such forward-looking information.
- This presentation and its contents are confidential and are being provided solely for informational purposes and may not be retransmitted. This presentation is being furnished solely for informational purposes and may not be reproduced or redistributed to any other person. In giving this presentation, the Company does not undertake any obligation to provide the recipient with access to any additional information or to update this presentation or any additional information or to correct any inaccuracies in any such information which may become apparent.
- Information on companies other than the Company and information provided from third parties are based on public information or sources. The Company has not independently verified the accuracy and appropriateness of such data and indicators used herein, nor does the Company assume any responsibility for the accuracy and appropriateness of such data and indicators presented in this presentation.
- This presentation does not contain all relevant information relating to the Company and the securities and is qualified in its entirety by reference to the detailed information appearing in the Japanese language prospectus (the “Japanese Prospectus”). Any investment decision with respect to the securities should be made solely upon the basis of the information contained in the Japanese Prospectus.

